Abstract
Background Plasma C-X-C-motif chemokine ligand-13 (CXCL13) has been linked to disease progression and mortality in people living with HIV (PLWH) and is a candidate target for immune-based strategies for HIV cure. Its role in central nervous system (CNS) of PLWH has not been detailed. We described CSF CXCL13 levels and its potential associations with neurological outcomes.
Methods Cross-sectional study enrolling PLWH without confounding for CXCL13 production. Subjects were divided according to CSF HIV-RNA in controllers (<20 cp/mL) and viremics. CSF CXCL13, and biomarkers of blood-brain barrier (BBB) impairment, intrathecal synthesis, and immune activation were measured by commercial immunoturbidimetric and ELISA assays. All subjects underwent neurocognitive assessment. Sensitivity analyses were conducted in subjects with intact BBB only.
Results 175 subjects were included. Prevalence of detectable CSF CXCL13 was higher in viremics (31.4%) compared to controllers (13.5%; OR 2.9 [1.4-6.3], p=0.006), but median CSF levels did not change (15.8 [8.2-91.0] vs 10.0 [8.1-14.2] pg/mL). In viremics (n=86), CXCL13 associated with higher CSF HIV-RNA, proteins, neopterin, Tourtelotte index, and CSF-to-serum albumin ratio. In controllers (n=89), CXCL13 associated with higher CD4+T-cells count, CD4/CD8 ratio, CSF proteins, neopterin, and several intrathecal synthesis markers. Detection of CSF CXCL13 in controllers increased the likelihood of HIV-associated neurocognitive disorders (58.3% vs 28.6%, p=0.041) and HIV-related CNS disorders (8.3% vs 0%, p=0.011). Sensitivity analyses confirmed all these findings.
Conclusions CSF CXCL13 identified a subgroup of PLWH presenting increased CNS IgG synthesis, and immune activation. In controllers, CSF CXCL13 associated with increased likelihood of neurocognitive impairment and HIV-related CNS disorders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work received funding specifically dedicated to the Department of Medical Sciences from the Italian Ministry for Education University and Research (MIUR) under the programme Dipartimenti di Eccellenza 2018-2022 (project n.D15D18000410001)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The work has been approved by the Ethics Committee of San Luigi Hospital, Orbassano (PRODIN study, protocol code 103/2015, approved on 22 June 2015).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Statements and Declarations
Competing interests: the authors declare no competing interests for this work.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
